Challenges like low selectivity, potential off-target effects, and incomplete mechanism insights explain why DYRK1A inhibitors, despite encouraging in vitro and animal model outcomes, have not advanced to clinical trials for diabetes therapy (Wang et al
"If you had a good experience, you're less likely to be writing about it online
For patients with suspected DVT, CVR offers same-day rule-out evaluation
Our findings demonstrate significant reductions in mortality, MAKE, and MALO across diverse patient populations, suggesting that this therapeutic approach could represent a paradigm shift in MASLD management
Strong regulatory framework and structured disease management programs boost the growth
The short half-life of native GLP-1 and advances in biochemical engineering led to the development of GLP-1 receptor agonists (GLP-1RAs)